Business Description
Nymox Pharmaceutical Corp
NAICS : 325412
SIC : 2835
ISIN : BSP733981026
Description
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and low-grade localized prostate cancer. The company also has an extensive patent portfolio covering its investigational drug as well as other therapeutic and diagnostic indications. It also has U.S. and patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The company operates in one reportable segment, focused on researching and developing products for the aging population.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.19 | |||||
9-Day RSI | 53.2 | |||||
14-Day RSI | 54.05 | |||||
3-1 Month Momentum % | 33.33 | |||||
6-1 Month Momentum % | 34 | |||||
12-1 Month Momentum % | -16.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History |
|---|
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:NYMXF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nymox Pharmaceutical Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.02 | ||
| Beta | 16.7888 | ||
| 3-Year Sharpe Ratio | 0.6 | ||
| 3-Year Sortino Ratio | 61.69 | ||
| Volatility % | 189.01 | ||
| 14-Day RSI | 54.05 | ||
| 14-Day ATR ($) | 0.019622 | ||
| 20-Day SMA ($) | 0.11264 | ||
| 12-1 Month Momentum % | -16.23 | ||
| 52-Week Range ($) | 0.03 - 0.1999 | ||
| Shares Outstanding (Mil) | 94.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nymox Pharmaceutical Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nymox Pharmaceutical Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-16 | In 128 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 34 days | ||
| General meeting for 2025 | 2026-07-13 | In 2 days | ||
| First quarter earnings results for 2026 | 2026-07-10 | 0.12 (+0.00%) | ||
| Annual report for 2024 | 2025-06-11 | 0.10 (+0.00%) | ||
| Third quarter earnings results for 2024 | 2025-02-05 | 0.10 (+21.95%) | ||
| Annual report for 2023 | 2024-08-29 | 0.00 (+0.00%) |
Show
Entries
Nymox Pharmaceutical Corp Frequently Asked Questions
What is Nymox Pharmaceutical Corp(NYMXF)'s stock price today?
The current price of NYMXF is $0.12. The 52 week high of NYMXF is $0.20 and 52 week low is $0.03.
When is next earnings date of Nymox Pharmaceutical Corp(NYMXF)?
The next earnings date of Nymox Pharmaceutical Corp(NYMXF) is 2026-08-14 Est..
Does Nymox Pharmaceutical Corp(NYMXF) pay dividends? If so, how much?
Nymox Pharmaceutical Corp(NYMXF) does not pay dividend.
Guru Commentaries on OTCPK:NYMXF
No articles.
Articles on Nymox Pharmaceutical Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers